Your browser doesn't support javascript.
loading
The added value of PSMA PET/MR radiomics for prostate cancer staging.
Solari, Esteban Lucas; Gafita, Andrei; Schachoff, Sylvia; Bogdanovic, Borjana; Villagrán Asiares, Alberto; Amiel, Thomas; Hui, Wang; Rauscher, Isabel; Visvikis, Dimitris; Maurer, Tobias; Schwamborn, Kristina; Mustafa, Mona; Weber, Wolfgang; Navab, Nassir; Eiber, Matthias; Hatt, Mathieu; Nekolla, Stephan G.
Afiliação
  • Solari EL; School of Medicine, Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University Munich, Munich, Germany. elucas.solari@tum.de.
  • Gafita A; School of Medicine, Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University Munich, Munich, Germany.
  • Schachoff S; School of Medicine, Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University Munich, Munich, Germany.
  • Bogdanovic B; School of Medicine, Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University Munich, Munich, Germany.
  • Villagrán Asiares A; School of Medicine, Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University Munich, Munich, Germany.
  • Amiel T; School of Medicine, Department of Urology, Klinikum rechts der Isar, Technical University Munich, Munich, Germany.
  • Hui W; School of Medicine, Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University Munich, Munich, Germany.
  • Rauscher I; School of Medicine, Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University Munich, Munich, Germany.
  • Visvikis D; INSERM, UMR 1101, LaTIM, Univ Brest, Brest, France.
  • Maurer T; Department of Urology and Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
  • Schwamborn K; School of Medicine, Institute of Pathology, Klinikum rechts der Isar, Technical University Munich, Munich, Germany.
  • Mustafa M; School of Medicine, Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University Munich, Munich, Germany.
  • Weber W; School of Medicine, Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University Munich, Munich, Germany.
  • Navab N; School of Computer Science, Computer Aided Medical Procedures and Augmented Reality, Technical University Munich, Munich, Germany.
  • Eiber M; School of Medicine, Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University Munich, Munich, Germany.
  • Hatt M; INSERM, UMR 1101, LaTIM, Univ Brest, Brest, France.
  • Nekolla SG; School of Medicine, Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University Munich, Munich, Germany.
Eur J Nucl Med Mol Imaging ; 49(2): 527-538, 2022 01.
Article em En | MEDLINE | ID: mdl-34255130
ABSTRACT

PURPOSE:

To evaluate the performance of combined PET and multiparametric MRI (mpMRI) radiomics for the group-wise prediction of postsurgical Gleason scores (psGSs) in primary prostate cancer (PCa) patients.

METHODS:

Patients with PCa, who underwent [68 Ga]Ga-PSMA-11 PET/MRI followed by radical prostatectomy, were included in this retrospective analysis (n = 101). Patients were grouped by psGS in three categories ISUP grades 1-3, ISUP grade 4, and ISUP grade 5. mpMRI images included T1-weighted, T2-weighted, and apparent diffusion coefficient (ADC) map. Whole-prostate segmentations were performed on each modality, and image biomarker standardization initiative (IBSI)-compliant radiomic features were extracted. Nine support vector machine (SVM) models were trained four single-modality radiomic models (PET, T1w, T2w, ADC); three PET + MRI double-modality models (PET + T1w, PET + T2w, PET + ADC), and two baseline models (one with patient data, one image-based) for comparison. A sixfold stratified cross-validation was performed, and balanced accuracies (bAcc) of the predictions of the best-performing models were reported and compared through Student's t-tests. The predictions of the best-performing model were compared against biopsy GS (bGS).

RESULTS:

All radiomic models outperformed the baseline models. The best-performing (mean ± stdv [%]) single-modality model was the ADC model (76 ± 6%), although not significantly better (p > 0.05) than other single-modality models (T1w 72 ± 3%, T2w 73 ± 2%; PET 75 ± 5%). The overall best-performing model combined PET + ADC radiomics (82 ± 5%). It significantly outperformed most other double-modality (PET + T1w 74 ± 5%, p = 0.026; PET + T2w 71 ± 4%, p = 0.003) and single-modality models (PET p = 0.042; T1w p = 0.002; T2w p = 0.003), except the ADC-only model (p = 0.138). In this initial cohort, the PET + ADC model outperformed bGS overall (82.5% vs 72.4%) in the prediction of psGS.

CONCLUSION:

All single- and double-modality models outperformed the baseline models, showing their potential in the prediction of GS, even with an unbalanced cohort. The best-performing model included PET + ADC radiomics, suggesting a complementary value of PSMA-PET and ADC radiomics.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Imageamento por Ressonância Magnética Multiparamétrica Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans / Male Idioma: En Revista: Eur J Nucl Med Mol Imaging Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Imageamento por Ressonância Magnética Multiparamétrica Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans / Male Idioma: En Revista: Eur J Nucl Med Mol Imaging Ano de publicação: 2022 Tipo de documento: Article